🇺🇸 FDA

Intelligence Platform

Patents

Browse 15 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11319356

Interferon alpha 2B variants

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11253591

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117975

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10981986

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822422

Antibodies against TL1a and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544199

Interferon alpha 2B variants

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963515

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9636334

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9611322

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9505826

Modified antibody with improved half-life

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127057

Anti-IL-23 heterodimer specific antibodies

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8932588

Treatment of cancer involving mutated KRAS or BRAF genes

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8901279

Humanized antibodies with anti-tumor activity

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted